Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.51 |
| ▸ | NMT1 | P30419 | 11/20 | 0.43 |
| ▸ | NMT2 | O60551 | 10/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30788352 | 0.90 | PTGS1 (0.50) | PTGS1GSTK1NMT1NMT2GLO1 | |
| SCHEMBL30443909 | 0.88 | NMT1 (0.45) | PTGS1GSTK1NMT1NMT2GLO1 | |
| SCHEMBL31665964 | 0.87 | NMT1 (0.50) | PTGS1GSTK1NMT1NMT2TLR2 | |
| SCHEMBL29569342 | 0.87 | PTGS1 (0.43) | PTGS1GSTK1NMT1NMT2GLO1 | |
| SCHEMBL29569500 | 0.87 | PTGS1 (0.43) | PTGS1GSTK1NMT1NMT2GLO1 | |
| SCHEMBL29569082 | 0.87 | PTGS1 (0.43) | PTGS1GSTK1NMT1NMT2GLO1 | |
| SCHEMBL24049252 | 0.87 | NMT1 (0.48) | NMT1NMT2GLO1 | |
| SCHEMBL30788344 | 0.86 | PTGS1 (0.50) | PTGS1GSTK1NMT1NMT2TLR2 | |
| SCHEMBL30513899 | 0.86 | PTGS1 (0.52) | PTGS1GSTK1NMT1NMT2TLR2 | |
| SCHEMBL31031501 | 0.86 | NMT1 (0.44) | PTGS1GSTK1NMT1NMT2GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | GLO PHARMA, INC. | 2024-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNB1, CHRNG, CHRNA1 | PTGS1 4293/4885GSTK1 4563/4885NMT1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.